Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
Park SH, et al. Among authors: lee sh, lee sj, lee sy, lee jh.
Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:35-44. doi: 10.1586/17474124.2015.1091309.
Expert Rev Gastroenterol Hepatol. 2015.
PMID: 26395533
Clinical Trial.